Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Genmab A/S (GMAB)

25.01   0.75 (3.09%) 02-20 16:00
Open: 24.7 Pre. Close: 24.26
High: 25.1389 Low: 24.33
Volume: 980,005 Market Cap: 15801M
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the trea

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 25.155 - 25.229 25.229 - 25.313
Low: 24.105 - 24.196 24.196 - 24.297
Close: 24.848 - 24.987 24.987 - 25.142

Technical analysis

as of: 2020-02-20 4:40:21 PM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 29.36     One year: 34.30
Support: Support1: 23.34    Support2: 22.23
Resistance: Resistance1: 25.14    Resistance2: 29.36
Pivot: 23.96
Moving Average: MA(5): 24.22     MA(20): 23.64
MA(100): 22.23     MA(250): 19.85
MACD: MACD(12,26): 0.46     Signal(9): 0.40
Stochastic oscillator: %K(14,3): 84.71     %D(3): 79.89
RSI: RSI(14): 71.48
52-week: High: 25.14  Low: 16.33  Change(%): 52.9
Average Vol(K): 3-Month: 31557  10-Days: 47481

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.
GMAB has closed above the upper band by 7.7%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 12.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Genmab earns $150M Darzalex milestone from J&J
Triggered by the achievement of $3B in global Darzalex (daratumumab) sales in 2019, Genmab A/S (NASDAQ:GMAB) earns a $150M milestone payment from Johnson &

Genmab Announces 2019 Net Sales Figures for DARZALEX® (daratumumab) and Achievement of USD 150 Million Sales Milestone in DARZALEX Collaboration with Janssen
Company Announcement Net trade sales of DARZALEX in 2019 totaled USD 2,998 millionGenmab to receive milestone payment of USD 150 million in DARZALEX…

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NasdaqGS
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 649.11
Shares Float (M) 642.32
% Held by Insiders
% Held by Institutions 3.67
Shares Short (K) 669
Shares Short P. Month (K)

Stock Financials

Book Value (p.s.)
PEG Ratio
Profit Margin 41.97
Operating Margin
Return on Assets (ttm) 7.1
Return on Equity (ttm) 15.6
Qtrly Rev. Growth 73.7
Gross Profit (p.s.) 4.668
Sales Per Share
EBITDA (p.s.)
Qtrly Earnings Growth 199.70
Operating Cash Flow (M)
Levered Free Cash Flow (M)

Stock Valuations

P/E Growth Ratio

Dividends & Splits

Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date 2018-04-30
Last Split Ratio 5
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2019 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.